VENUS REMEDIES share price has zoomed 7% and is presently trading at Rs 366.6.
Meanwhile, the BSE HEALTHCARE index is at 41,977.1 (down 0.1%).
Among the top gainers in the BSE HEALTHCARE index today are AARTI DRUGS (up 7.6%) and HIKAL CHEMIC (up 3.2%).
GSK Pharma (down 3.0%) and Procter & Gamble Health (down 2.7%) are among the top losers today.
Over the last one year, VENUS REMEDIES has moved up from Rs 239.7 to Rs 366.6, registering a gain of Rs 126.9 (up 52.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,021.8 to 41,977.1, registering a gain of 49.8% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 130.7%), Glenmark Pharma (up 114.5%) and GSK Pharma (up 111.6%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,010.4 (up 0.1%).
The top gainers among the BSE Sensex today are Bharti Airtel (up 1.1%) and Asian Paints (up 0.8%). The most traded stocks in the BSE Sensex are Bharti Airtel and Tata Steel.
In the meantime, NSE Nifty is at 24,813.8 (up 0.2%). Grasim Industries and Tata Consumer Products are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,216.1 to 81,010.4, registering a gain of 15,794.3 points (up 24.2%).
VENUS REMEDIES net profit grew 3.4% YoY to Rs 12 million for the quarter ended June 2024, compared to a profit of Rs 12 million a year ago. Net sales rose 14.1% to Rs 1,086 million during the period as against Rs 952 million in April-June 2023.
For the year ended March 2023, VENUS REMEDIES reported 34.8% decrease in net profit to Rs 266 million compared to net profit of Rs 407 million during FY22. Revenue of the company fell 7.4% to Rs 5,555 million during FY23.
The current Price to earnings ratio of VENUS REMEDIES, based on rolling 12 month earnings, stands at 17.2.
Equitymaster requests your view! Post a comment on "VENUS REMEDIES Gains 7%; BSE HEALTHCARE Index Down 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!